search for


Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Systematic Review and Meta-analysis
International Journal of Stem Cells
Published online February 28, 2018;  
© 2018 Korean Society for Stem Cell Research.

Hyunsuk Jeong1, Hyeon Woo Yim1, Hun-Jun Park2, Youngseung Cho1, Hanter Hong3, Na Jin Kim4, Il-Hoan Oh5

1Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Cheong-yang Branch Office of the Community Health Center, Cheongyang, Korea
4Medical Library, The Catholic University of Korea, Seoul, Korea
5Catholic High-Performance Cell Therapy Center & Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul, Korea
Correspondence to: Hyeon Woo Yim
Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, 222 Banpo-dero, Seocho-gu, Seoul 06591, Korea
Tel: +82-2-2258-7860, Fax: +82-2-532-3820
; Accepted January 25, 2018.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background and Objectives: Mesenchymal stem cells (MSC) have emerged as breakthrough treatments for myocardial infarction. However, the efficacy of MSC remains unclear. The aim of the study was to evaluate treatment effect of MSC in terms of mechanical, regenerative, and clinical outcomes for patients with myocardial infarction (MI) using meta-analysis. Methods: A systematic search and critical review of MEDLINE, EMBASE, and Cochrane database literature published from inception through December 2017 was performed. The inclusion criteria were randomized controlled trials, studies on patients with myocardial infarction, and studies compared with placebo as a control group. Results: A total of 950 patients from 14 randomized placebo controlled trials were included in the final meta-analysis. MSC treatment showed benefits for mechanical, regenerative, and clinical outcomes. In terms of mechanical outcomes, the LVEF of the MSC treatment group increased by 3.84% (95% CI: 2.32∼5.35, I2=43) and the effect was maintained for up to 24 months. Regenerative outcomes were measured by scar mass and WMSI. Scar mass was reduced by −1.13 (95% CI: −1.80 to −0.46, I2=71) and WMSI was reduced by −0.05 (95% CI: −0.07 to −0.03, I2=45) at 6 months after MSC treatment. Mortality rate and incidence of re-hospitalization for HF in MSC group patients trended toward reduced incidence compared to the control group, although this was not statistically significant because of the low event rate. Conclusions: The findings of this meta-analysis indicate that MSCs can be beneficial in improving heart function in the treatment of MI. However, the efficacy of MSCs must be further explored through large randomized controlled trials based on rigorous research design.
Keywords : Mesenchymal stem cell, Myocardial infarction, Systematic review, Meta-analysis

November 2017, 10 (2)